$16.87
▲ +0.1% Today
as of Jul 22, 16:54 ET
Last 30 days
Recent Press Releases & News
mixed
▲ 1
● 12
▼ 0
Takeda Pharmaceutical Reports Positive Phase 3 Data for Zasocitinib in Moderate-to-Severe Plaque Psoriasis
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies
Takeda and Indonesia partner on plasma-derived therapies
Overview
52-week range
$13
$19
66% of range
Avg surprise (last 3)
+3.5%
Avg reaction (last 2)
-2.0%
50% positive
Latest IV / EM
27%
EM ±6.2% · $18 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 13, 2026 | Mar/2026 | $0.28 | $0.21 | +33.3% | +75.0% | +1.3% | earnings |
| Wed Jul 30, 2025 | Jun/2025 | $0.52 | $0.47 | +10.6% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $0.16 | $0.24 | -33.3% | — | -5.2% | earnings |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Jul 30, 2026 | Jun/2026 | BMO | $0.41 | $0.52 | -21.1% |